IP
CRVS icon

Intellectus Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Intellectus Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,700
Closed -$11K – 221
2019
Q1 		$11K Buy
2,700
+500
+23% +$2.11K ﹤0.01% 340
2018
Q4 		$8K Sell
2,200
-250
-10% -$1.71K 0.01% 209
2018
Q3 		$21K Hold
2,450
– – 0.01% 429
2018
Q2 		$27K Hold
2,450
– – 0.01% 395
2018
Q1 		$28K Hold
2,450
– – 0.01% 396
2017
Q4 		$25K Buy
2,450
+2,360
+2,622% +$30.2K 0.01% 407
2017
Q3 		$1K Sell
90
-1,392
-94% -$19.3K ﹤0.01% 752
2017
Q2 		$18K Buy
+1,482
New +$15.8K 0.01% 524

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CI
Cowen Inc New York $1.35B AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return